EDI-200

N/A

Report date: 2022/10/25 20:00:47

Base Information

Drug NameEDI-200
Drug Alias NameRecombinant EDA1Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion proteinHypohidrotic ectodermal dysplasia therapy - EdimerRecombinant ectodysplasin A1Fc:EDA-A1 fusion protein +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor receptor agonists
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsEctodermal Dysplasia 1, Anhidrotic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApoxis
China Registration ClassN/A

Develop Information

Active CompaniesEsperare FoundationPierre Fabre Medicament
Inactive CompaniesEdimer Pharmaceuticals Inc
Active IndicationsEctodermal Dysplasia 1, Anhidrotic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A